Natera director Marcus Gail boxer sells $563,100 in stock

On April 1, 2025, Marcus Gail Boxer, a director at Natera, Inc. (NASDAQ:NTRA), executed a series of stock transactions involving the company’s common shares. The transactions included the sale of 4,000 shares, generating a total of $563,100. The sale prices ranged from approximately $139.33 to $142.82 per share, near the current trading price of $138.68. According to InvestingPro analysis, the stock has shown significant volatility and delivered an impressive 50% return over the past year.

In addition to the sales, Boxer acquired shares through stock option exercises. He acquired 4,000 shares at prices ranging between $7.86 and $24.42 per share, amounting to a total transaction value of $78,967. With Natera’s next earnings report scheduled for May 7, 2025, InvestingPro subscribers can access comprehensive insider trading analysis and 11 additional ProTips to make informed investment decisions.

These transactions were conducted as part of a pre-established Rule 10b5-1 trading plan. Following these activities, Boxer holds 9,704 shares of Natera directly. The company, currently valued at $18.83 billion, maintains a GREAT financial health score according to InvestingPro metrics.

In other recent news, Natera Inc . reported strong financial results for the fourth quarter of 2024, with revenue reaching $476 million, a 53% increase year-over-year, exceeding the forecasted $409.89 million. The company also posted a narrower-than-expected loss per share of -$0.41, better than the anticipated -$0.49. Gross margins improved significantly to 63%, up from 51% the previous year, and the company generated $46 million in cash flow during the quarter. Analysts at TD Cowen and Canaccord Genuity have shown confidence in Natera’s prospects, maintaining a Buy rating and setting a price target of $195, citing the company’s compelling 2025 sales guidance and strong growth levers.

Natera’s recent advancements include the initiation of the HEROES clinical trial, sponsored by Unicancer and funded by the French Ministry of Health, to explore treatment de-escalation in metastatic HER2+ breast cancer patients. The trial will use Natera’s Signatera test to guide therapy decisions based on circulating tumor DNA status. Additionally, Natera achieved positive operating cash flows for the fourth consecutive quarter, indicating consistent financial performance. The company has also seen significant growth in test volumes, supported by a solid average selling price and one-time financial adjustments.

Canaccord Genuity noted that Natera’s initial 2025 guidance suggests year-over-year revenue growth in the mid-20% range, with expectations of continued strong gross margins and positive cash flow. The firm also highlighted potential benefits from improved Medicare Advantage rates and biomarker legislation expected in 2025. These recent developments underscore Natera’s robust position in the genetic testing industry and its strategic focus on expanding its product offerings and market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.